Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

HEALTH CANADA GRANTS LSL PHARMA GROUP APPROVAL TO COMMERCIALIZE SIX NEW STERILE OPHTHALMIC SOLUTIONS

By The Northwire Desk — AI Analysis Oct 28, 2025 · 07:00 LSL · 0.36 LSL Pharma Group Inc.
LSL · Price

Executive Summary

  • Health Canada approved LSL Pharma Group’s first six sterile ophthalmic solutions for glaucoma and allergy treatment.
  • Commercial launch is slated for Q2 2026, targeting an aggregate Canadian market opportunity of $66 million (IQVIA 2025 data).
  • The approvals represent a strategic milestone for the company’s Steri‑Med Pharma division and support its growth plan to expand its eye‑care portfolio.

Key Details

  • Six sterile ophthalmic products received Health Canada approval on Oct. 28, 2025.
  • Products are intended for treatment of glaucoma and allergic eye conditions.
  • Expected commercial launch: Q2 2026.
  • Aggregate addressable market in Canada estimated at $66 million (IQVIA 2025).
  • CEO François Roberge highlighted the approvals as a “significant step forward” for the Steri‑Med Pharma division and a foundation for broader eye‑care product expansion.
  • The approval underscores LSL Pharma’s capability to complete complex regulatory projects in compliance with Canadian standards.

Notable Quotes

“Obtaining these approvals from Health Canada represents a significant step forward for our Steri-Med Pharma division and another important step in the implementation of LSL Pharma's growth plan,” – François Roberge, President & CEO.

Read the original news release →

More from LSL Pharma Group Inc.

May 28, 2026 · 07:00

Revenue Growth Masks Profitability Concerns as Operational Scaling Continues

Production / Operations May 25, 2026 · 12:00

Revenue Surge Masks Cash Burn Risk as Integration Costs Mount

Earnings May 25, 2026 · 07:00

Revenue Surge Masks Integration Costs as LSL Pharma Tests Regulatory Resilience

Earnings Apr 30, 2026 · 07:00

LSL Pharma Delivers Revenue Surge But Profitability Erosion Signals Costly Growth Phase

Earnings Apr 09, 2026 · 07:00

Juno OTC secures Loratadine RDT partnership, expanding Canadian OTC pipeline

M&A / Property Jan 28, 2026 · 16:07

LSL obtains FDA certification for ophthalmic ointments

Production / Operations